Erik Penser Bank AB (publ) (”Erik Penser Bank”) notifies that stabilisation measures have been undertaken in Ascelia Pharma AB’s (publ) (”Ascelia Pharma” or the “Company”) shares on Nasdaq Stockholm.
As announced in connection with the offering to acquire newly issued shares in the Company and the listing of the Company’s shares on Nasdaq Stockholm (the ”Offering”), Erik Penser Bank may, acting as stabilisation manager, carry out transactions aimed at supporting the market price of the shares at levels above those which might otherwise prevail in the open market.
Stabilisation transactions may be undertaken on Nasdaq Stockholm, in the over-the-counter market or otherwise, at any time during the period starting on the date of commencement of trading in the shares on Nasdaq Stockholm and ending no later than 30 calendar days thereafter. However, Erik Penser Bank is not required to undertake any stabilisation and there is no assurance that stabilisation will be undertaken. Stabilisation, if undertaken, may be discontinued at any time without prior notice. In no event will transactions be effected at levels above the price in the Offering.
The board of directors of the Company has granted Erik Penser Bank an over-allotment option, which may be utilized in whole or in part for 30 days from the first day of trading in the Company’s shares on Nasdaq Stockholm, to issue up to 1,200,000 shares, corresponding to up to 15 per cent of the total number of shares encompassed by the Offering, at a price corresponding to the price in the Offering, i.e. 25 SEK, to cover any over-allotment in connection with the Offering.
Erik Penser Bank has, in its capacity as stabilisation manager, notified that stabilisation measures have been undertaken, in accordance with article 5(4) in the Market Abuse Regulation 596/2014, on Nasdaq Stockholm as specified below. Undertaken stabilization measures were also announced on 21 March 2019. The contact person at Erik Penser Bank is Oskar Ekman, telephone: +46 8 463 80 36.
|Issuer:||Ascelia Pharma AB|
|Securities:||Shares (ISIN SE0010573113|
|Offering size*:||9,200,000 shares|
|Offer price:||SEK 25|
|Stabilisation manager:||Erik Penser Bank AB (publ)|
* The base offering size amounted to up to 8,000,000 shares and the over-allotment option amounts to up to 1,200,000 shares.
|Date||Quantity||Price (highest)||Price (lowest)||Price (volume weighted average)||Currency||Trading venue|
For more information, please contact
Magnus Corfitzen, CEO
Tel: +46 735 179 110
Mikael Widell, IR & Communications Manager
Tel: +46 703 11 99 60
This information is such information as Ascelia Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 6.45 p.m CET on 1 April 2019.
About Ascelia Pharma
Ascelia Pharma is an oncology-dedicated orphan drug development company located in Malmö, Sweden. The company’s strategy is to develop drugs, which target unmet medical needs, have an established mode of action and a relatively low development risk. Ascelia Pharma has two drug candidates – Mangoral® and Oncoral – currently under development.
Mangoral is a novel contrast agent for MR-scans and is ready for Phase III clinical studies. Mangoral is developed to improve the visualization of focal liver lesions (liver metastases) in patient with impaired kidneys that cannot tolerate current gadolinium contrast agents on the market. Oncoral is an oral chemotherapy tablet ready for Phase II for the treatment of gastric cancer. Ascelia Pharma is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com
This announcement is not and does not form a part of any offer for sale or purchase of securities.
This announcement is not being made and may not be released, published or distributed, directly or indirectly, into the United States of America, Australia, Canada, Japan or any other jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), and accordingly may not be offered or sold in the United States absent registration or an exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any offering in the United States or to conduct a public offering of securities in the United States.
The offering of securities referred to in this announcement has been made by means of a prospectus. This announcement is not a prospectus for the purposes of Directive 2003/71/EC (together with any applicable implementing measures in any Member State, the “Prospectus Directive”). Investors should not invest in any securities referred to in this announcement except on the basis of information contained in the aforementioned prospectus.